Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
This shift can quietly reshape demand dynamics for its shares. See our latest analysis for Bicara Therapeutics. The latest index inclusions come after a powerful 90 day share price return of 64.02 percent from a current share price of 17.55 dollars, even though the 1 year total shareholder return is still negative. This suggests that momentum has only recently started to build. If you are watching how biotech sentiment shifts around catalysts like index additions, this could be a smart moment to compare Bicara with other healthcare stocks that are catching investors attention. With the stock still trading at a steep discount to analyst targets despite sharp recent gains, the real question is whether Bicara is quietly undervalued, or if the market is already discounting its next leg of growth. At a last close of 17.55 dollars, Bicara trades at a 2.5 times price to book multiple, signaling a discount versus both peers and the broader US biotech space. The price to book ratio
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at Mizuho to a "hold" rating.MarketBeat
- Bicara Therapeutics (NASDAQ:BCAX) was given a new $18.00 price target on by analysts at Mizuho.MarketBeat
- Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12GlobeNewswire
- Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026GlobeNewswire
BCAX
Earnings
- 11/10/25 - Miss
BCAX
Sec Filings
- 12/23/25 - Form 4
- 12/22/25 - Form 144
- 12/18/25 - Form 4
- BCAX's page on the SEC website